Search
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORBRENA® 100 MGImipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigational[label] It is stable to many beta-lactamases. … Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]
Mixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUNCategories: Heterocyclic Compounds, 2-RingTroglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesVoclosporin
go.drugbank.com/drugs/DB11693ApprovedInvestigationalEarly intervention with voclosporin coupled with a kidney response is believed to prevent irreversible damage to the kidney and lead to better long-term clinical outcomes for patients with LN. … [A227683] Voclosporin, marketed as Lupkynis, is a calcineurin-inhibitor immunosuppressant for the treatment of LN.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDihydrotachysterol
go.drugbank.com/drugs/DB01070ApprovedWithdrawnA vitamin D that can be regarded as a reduction product of vitamin D2.
Categories: Vitamin D and AnaloguesCoagulation Factor IX Human
go.drugbank.com/drugs/DB13152ApprovedInvestigationalFactor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.
Mixtures: AlphaNine SD, AlphaNine SDCategories: coagulation factor IX, II, VII and X in combinationBuclizine
go.drugbank.com/drugs/DB00354ApprovedBuclizine is an antihistamine medication with both antiemetic and anticholinergic effects [L6220], belonging to the _piperazine derivative_ family of drugs. … [L6217] Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-(p-tert-Butylbenzyl)-4-(4-chloro-alpha-phenylbenzyl)piperazineMeglumine
go.drugbank.com/drugs/DB09415ApprovedInvestigationalMixtures: UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 100 ML, UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 50 MLCategories: Compounds used in a research, industrial, or household settingRecombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L49560] It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants.[L49555] … The vaccine comprises two antigens - the other being [recombinant stabilized RSV A prefusion F antigen] - which have been expressed in Chinese hamster ovary cell lines and then purified and lyophilized
Synonyms: Recombinant stabilized RSV A prefusion F antigen, RSV subgroup A stabilized prefusion F proteinSerdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma … [A230698, A230703] The underlying cause of ADHD is unclear but likely involves dysfunction in dopaminergic and noradrenergic neurotransmission, as evidenced by the clear beneficial effect of CNS stimulants